Korean J Gastroenterol.  2016 Apr;67(4):216-219. 10.4166/kjg.2016.67.4.216.

A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient

• Song JH
• Kim SY
• Shin JK
• Hong SD
• Rim KS
• Park HN
• Lee JH
• Lee YB
• Oh SH
• Hwang SG

• KMID: 2373428
• DOI: http://doi.org/10.4166/kjg.2016.67.4.216

Abstract

Entecavir (Baraclude®) is an oral antiviral drug used for the treatment of HBV. Entecavir is a reverse transcriptase inhibitor which prevents the HBV from multiplying. Most common adverse reactions caused by entecavir are headache, fatigue, dizziness, and nausea. Until now, there has been no report of peripheral neuropathy as a side effect associated with entecavir treatment. Herein, we report a case of peripheral neuropathy which probably occurred after treatment with entecavir in a hepatitis B patient. The possibility of the occurrence of this side effect should be carefully taken into consideration when a patient takes a high dose of entecavir for a long period of time or has risk factors for neuropathy at the time of initiating entecavir therapy.

Keyword

Entecavir; Polyneuropathies; Hepatitis B

MeSH Terms

Administration, Oral
Antiviral Agents/*adverse effects/therapeutic use
Brain/diagnostic imaging
Drug Therapy, Combination
Duloxetine Hydrochloride/therapeutic use
Glucocorticoids/therapeutic use
Guanine/adverse effects/*analogs & derivatives/therapeutic use
Hepatitis B, Chronic/drug therapy
Humans
Male
Middle Aged
Polyneuropathies/*diagnosis/drug therapy/etiology
Prednisolone/therapeutic use
Pregabalin/therapeutic use
Tomography, X-Ray Computed
Antiviral Agents
Duloxetine Hydrochloride
Glucocorticoids
Guanine
Prednisolone
Pregabalin

Reference

References

1. Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother. 2002; 46:2525–2532.

2. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother. 1998; 42:3200–3208.

3. Manns MP, Akarca US, Chang TT, et al. Longterm safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf. 2012; 11:361–368.

4. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009; 50:2001–2006.

5. Zhang XH, Wu YK, Cao H, Wu ZB, Ke WM. Clinical characterization of peripheral neuropathy associated with entecavir in patients with HBV-induced cirrhosis. Zhonghua Gan Zang Bing Za Zhi. 2012; 20:707–708. Chinese.

6. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatmentnaïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010; 52:176–182.

7. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011; 54:91–100.

8. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007; 133:1437–1444.

9. Chang TT, Gish RG, de Man R, et al. BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354:1001–1010.